<i>RAC1</i> Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient

<i>RAC1</i> Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient

<i>BRAF</i>-activating mutations are the most frequent driver mutations in papillary thyroid cancer (PTC). Targeted inhibitors such as dabrafenib have been used in advanced <i>BRAF</i>-mutated PTC; however, acquired resistance to the drug is common and little is known about o...

Full description

Bibliographic Details
Main Authors: Rozita Bagheri-Yarmand, Naifa L. Busaidy, Elena McBeath, Brian P. Danysh, Kurt W. Evans, Tyler J. Moss, Argun Akcakanat, Patrick K. S. Ng, Christina M. Knippler, Jalyn A. Golden, Michelle D. Williams, Asha S. Multani, Maria E. Cabanillas, Kenna R. Shaw, Funda Meric-Bernstam, Manisha H. Shah, Matthew D. Ringel, Marie Claude Hofmann
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
papillary thyroid carcinoma
anaplastic thyroid carcinoma
BRAF
RAC1
PAK1
aneuploidy
Online Access:https://www.mdpi.com/2072-6694/13/19/4950

Internet

https://www.mdpi.com/2072-6694/13/19/4950

Similar Items